Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Ceritinib

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 19,609Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IPAB stays revocation of Novartis’ patent on anti-cancer drug Ceritinib
    IPAB stays revocation of Novartis’ patent on anti-cancer drug Ceritinib

    12 Aug 2020

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=130353&sid=1

    PHARMABIZ
    12 Aug 2020
    Share Share
    NICE final guidance backs Pfizer's Lorviqua
    NICE final guidance backs Pfizer's Lorviqua

    13 May 2020

    // Selina McKee PHARMA TIMES

    http://www.pharmatimes.com/news/nice_final_guidance_backs_pfizers_lorviqua_1340196

    Selina McKee PHARMA TIMES
    13 May 2020
    Share Share
    Novartis, Pfizer, AZ and more hand China 50%-plus cancer drug discounts
    Novartis, Pfizer, AZ and more hand China 50%-plus cancer drug discounts

    11 Oct 2018

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma-asia/big-pharma-s-cancer-drugs-take-50-plus-discount-for-china-s-insurance-scheme

    Angus Liu FIERCE PHARMA
    11 Oct 2018
    Share Share
    Preliminary NICE ‘no’ for Takeda’s Alunbrig
    Preliminary NICE ‘no’ for Takeda’s Alunbrig

    03 Oct 2018

    // Selina McKee PHARMA TIMES

    http://www.pharmatimes.com/news/preliminary_nice_no_for_takedas_alunbrig_1254340

    Selina McKee PHARMA TIMES
    03 Oct 2018
    Share Share
    Takeda's Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use
    Takeda's Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use

    26 Sep 2018

    // Carly Helfand FIERCE PHARMA

    https://www.fiercepharma.com/marketing/takeda-alk-drug-alunbrig-trounces-pfizer-s-xalkori-bid-for-earlier-use

    Carly Helfand FIERCE PHARMA
    26 Sep 2018
    Share Share
    Bristol-Myers to sell Opdivo in China at half-price: report
    Bristol-Myers to sell Opdivo in China at half-price: report

    22 Aug 2018

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma-asia/take-note-i-o-players-bristol-myers-to-sell-opdivo-china-at-half-its-u-s-price-report

    Angus Liu FIERCE PHARMA
    22 Aug 2018
    Share Share